Baker Bros. Advisors Files Amendment No. 14 to Schedule 13D for BeOne Medicines Ltd.

Executive Summary

On September 16, 2026, Baker Bros. Advisors LP filed Amendment No. 14 to Schedule 13D regarding its holdings in BeOne Medicines Ltd. (CIK: 0001651308). The amendment reports the exercise of share options by two former director representatives (Michael Goller and Ranjeev Krishana) pursuant to Proceeds Agreements with the Adviser, resulting in the acquisition of 30,768 American Depositary Shares (representing 399,984 Ordinary Shares) for a total consideration of $1,133,185.44.

---

Key Transaction Highlights

• Date of Event: September 14, 2026
• Option Exercises: 15,384 ADS options exercised by each of Ranjeev Krishana and Michael Goller at an exercise price of $36.83 per ADS ($566,592.72 each; $1,133,185.44 in aggregate).
• Financing: Funded through drawdowns of $94,095.86 from 667, L.P. and $1,039,089.58 from Baker Brothers Life Sciences, L.P. under respective revolving loan agreements.
• Aggregate Ownership: Baker Bros. Advisors LP and its GP beneficially own 115,457,154 Ordinary Shares (7.8%), while Julian C. Baker and Felix J. Baker report beneficial ownership of 115,912,814 Ordinary Shares (7.8%).

---

Impact & Significance

This filing represents standard administrative execution under pre-existing proceeds agreements covering former employee-directors rather than an open-market expansion of the core position. The overall percentage ownership remains steady at approximately 7.8%.